Evidence map›Paper›PMID 42559246›Full record

ArticleCureus2026

Biosimilar Nivolumab-Based Combination Therapy in Advanced Oral Cavity Squamous Cell Carcinoma: A Real-World Case Series of Five Patients.

Santhosh Meedimale, Soumya S Panda, Vipulkumar Thummar, Harsh Bhavsar

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Santhosh MeedimaleDepartment of Medical Oncology, Omega Hospitals, Karimnagar, IND.
Soumya S PandaDepartment of Medical Oncology, Institute of Medical Sciences (IMS) and SUM Hospital, Siksha 'O' Anusandhan (SOA) Deemed to be University, Bhubaneswar, IND.
Vipulkumar ThummarDepartment of Medical Affairs, Zydus Lifesciences Limited, Ahmedabad, IND.
Harsh BhavsarDepartment of Medical Affairs, Zydus Lifesciences Limited, Ahmedabad, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinomas of the head and neck (SCCHN) belongs to a biologically aggressive group of malignancies. The salvage options, after failure of the platinum-based therapy and immune checkpoint inhibitors (ICIs), are usually very limited. The regimen comprising oral methotrexate, erlotinib, and celecoxib (OMCT) has been explored as a well-tolerated, low-dose management option. We present through the case series the clinical outcomes of patients who had recurrent, refractory, or locally advanced SCCHN treated with OMCT in combination with low-dose nivolumab for translatable evidence.

Indexed as

head and neck neoplasmsimmunotherapyneoadjuvant therapynivolumabsquamous cell carcinoma

Identifiers

PMID42559246
PMCPMC13440562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.